Prof. Doriano Fabbro

Dr. Doriano Fabbro PhD is Chief Scientific Officer of PIQUR, a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs. After receiving his  PhD in cell biology and biochemistry at the University of Basel, he spent twelve years as Group Leader in Molecular Tumor Biology. H ethen joined the Oncology Group of Ciba-Geigy Basel. After the merger of Ciba-Geigy with Sandoz in 1996 he served at Novartis as Head of Kinase Biology until 2012. Doriano has contributed to the discovery and development of various protein kinase inhibitors for the treatment of cancer; e.g. Midostaurin®, Glivec®, Afinitor®, and Tasigna®. Doriano is author in more than 200 publications and numerous patents in the area of protein kinases regulation, structure, screening and drug discovery. He has been honoured with the Novartis Oncology President's Award (2005).